CAMBRIDGE, Mass., Feb. 16 10, 2022 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 24, 2022, at 8:00 a.m. ET to provide a company update and fourth quarter and full year 2021 results.
To access the conference call:
US callers should dial 877-407-0989 and international callers should dial 201-389-0921 approximately five minutes before the call starts. Participants should request to be connected to the Editas Medicine results conference call.
A live webcast and replay of the conference call is also available on the Investors section of Editas Medicine’s website at https://www.editasmedicine.com/.
About Editas Medicine As a leading genome editing company, Editas Medicine is focused on translating the power and potential of CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust portfolio treatments for people living with serious illnesses around the world. Editas Medicine aims to discover, develop, manufacture and commercialize precision, sustainable and transformative genomic medicines for a broad class of diseases. For the latest scientific information and presentations, please visit www.editasmedicine.com.
Media contact: Cristi Barnett (617) 401-0113 [email protected]
Investor Contact: Ron Moldaver (617) 401-9052 [email protected]